Evonik stock: analysis & valuation

EVK.DESpecialty ChemicalsGermanyData as of Nov 15, 2026
Metrics analysis · Specialty Chemicals

Evonik EVK.DE

Price 21.32 EUR +1.52%Market cap 9.9 bn EUR52 weeks 12.49 – 21.84
Forward P/E
13.9x
Industry 15.7x
EV/EBITDA
8.6x
Industry 11.9x
Revenue growth
12.8%
Industry 7.9%
Operating margin
5.4%
Industry 12.2%
Return on equity
2.2%
Industry 8.7%
Free cash flow yield
8.4%
Industry 3.5%

What does Evonik do?

Evonik is a German specialty chemicals group headquartered in Essen with a global presence. The company manufactures products that are used in other industries as intermediates or additives. These include silicas and silanes for tires and electronics, amino acids such as methionine and lysine for animal nutrition, hydrogen peroxide, and additives for coatings, adhesives and foams.

The business is divided into the segments Advanced Technologies, Custom Solutions and Infrastructure. Customers are mainly manufacturers in automotive, construction, consumer goods, pharmaceuticals, cosmetics and the animal feed industry. Competitively, Evonik positions itself through technological specialization, proximity to applications and leading market positions in niches. In standardized products such as feed amino acids, the company faces price competition from international providers, particularly from Asia. Competitors include large chemical groups such as BASF, Wacker, Dow and Arkema.

Score profile

Quality2.4
Valuation5.8
Growth6.2
Financial strength5.7
Momentum9.0

Rank vs. Specialty Chemicals (43 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Evonik ranks below average in the group Specialty Chemicals (2.4/10). On growth, the company ranks above average in the group Specialty Chemicals (6.2/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Specialty Chemicals (5.8/10). On financial strength, Evonik ranks in the middle in the group Specialty Chemicals (5.7/10).

MetricStockGroup medianRanking
Forward P/E13.9x15.7xbetter than 66 %
Trailing P/E57.6x29.6xbetter than 15 %
PEG ratio6.2x2.0xbetter than 4 %
EV/EBITDA8.6x11.9xbetter than 78 %
Price/sales0.7x1.6xbetter than 83 %
Price/book1.3x2.3xbetter than 80 %
Revenue growth12.8%7.9%better than 85 %
Earnings growth0.0%0.0%better than 39 %
Gross margin24.7%31.7%better than 31 %
Operating margin5.4%12.2%better than 17 %
Net margin1.2%5.3%better than 20 %
Return on equity2.2%8.7%better than 27 %
Debt/equity48.9%68.5%better than 77 %
Current ratio1.3x1.8xbetter than 13 %
Free cash flow yield8.4%3.5%better than 80 %
Dividend yield4.7%1.8%–
Payout ratio270.3%48.8%–
Beta0.500.86–

Valuation: what is Evonik worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Evonik a model range of 24.07 EUR to 50.00 EUR per share.

Price 21.32 EUR
Analysts 19.55 EUR
Fair value range 24.07 EUR – 50.00 EURMidpoint 32.41 EUR (+52.0% vs. price)

11 analysts, average rating “Hold”, average price target 19.55 EUR (−8.3%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Demand from customer industries such as automotive, construction, animal nutrition and electronics largely determines sales volumes.
  • Technologically differentiated specialty products enable better prices and margins than pure commodity chemicals.
  • Cost efficiency, plant utilization, and raw material and energy prices significantly affect profitability.

Risks

  • High energy and raw material costs at the German location can weigh on competitiveness against international providers.
  • Economic fluctuations in cyclical customer industries lead to volatile demand and price pressure.
  • Price competition in standardized products, as well as regulatory requirements and restructuring costs, can weigh on results.

What to look for with Evonik

The adjusted EBITDA margin is particularly informative, as it shows how well specialization and cost control convert prices into earnings in a cyclical, capital-intensive business.

Full AI analysis of Evonik

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Evonik stock

What is the P/E ratio of Evonik stock?

Based on expected earnings, Evonik trades at a P/E of 13.9x, compared with a median of 15.7x for the peer group Specialty Chemicals. Based on the earnings of the last twelve months it is 57.6x. (data as of Nov 15, 2026)

Does Evonik pay a dividend?

Yes. The dividend yield is currently 4.7%, with a payout ratio of 270.3% of earnings.

Is Evonik stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Evonik is currently valued roughly in line with the average of the companies in the group Specialty Chemicals (valuation score 5.8 out of 10). Our model calculations (DCF and industry multiples) give a range of 24.07 EUR to 50.00 EUR per share at a price of 21.32 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Evonik stock?

11 analysts have an average price target of 19.55 EUR (−8.3% vs. the current price); the average rating is “Hold”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.